File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Allogeneic bone marrow transplantation for adult acute lymphoblastic leukemia: A single-centre experience

TitleAllogeneic bone marrow transplantation for adult acute lymphoblastic leukemia: A single-centre experience
Authors
KeywordsAdult acute lymphoblastic leukemia
Bone marrow transplantation
Issue Date1998
PublisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/3182
Citation
Hematological Oncology, 1998, v. 16 n. 4, p. 163-168 How to Cite?
AbstractBetween 1990 and 1997, we performed 29 allogeneic BMTs for acute lymphoblastic leukemia (ALL) patients with HLA-identical sibs. Their median age was 31 years (range 15 to 43); there were 15 males and 14 females. The conditioning protocol was Cy-TBI (n= 15), VP16-Cy-TBI(n= 12), CBV (n= 1) and Bu-Cy (n = 1). Cyclosporin and methotrexate were used for GVHD prophylaxis. The median disease-free survival (DFS) was 12 months (range 1 to 92) with an actuarial 4-years DFS of 42.3 per cent. Three patientS died of transplant- related complications before 100 days. Relapse occurred in i 1 cases at a median time of 5 months (range 3 to 14). All nine patients relapsing within one year died form resistant leukemia. Three patients died of late treatment- related complications. There were 13 survivors (median follow-up 38 months, range 12-98), with 12 in remission. Only four had limited cGVHD, and all had 100 per cent performance scores. One patient also cleared her chronic hepatitis B carrier status due to acquired immunity. The DFS rates amongst CR1 cases and R1/CR2 cases were comparable (p=0.39). No long-term DFS is obtained from patients with resistant disease (n=4). The survival results for BMT at CR1 were superior to those using intensive chemotherapy consolidation (p=0.29), mainly due to poor late results in the chemotherapy arm. For young ALL patients with HLA-matched siblings, the option of BMT should be considered in light of local consolidation survival results.
Persistent Identifierhttp://hdl.handle.net/10722/78557
ISSN
2015 Impact Factor: 3.494
2015 SCImago Journal Rankings: 0.767
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorAu, WYen_HK
dc.contributor.authorLie, AKWen_HK
dc.contributor.authorMa, SKen_HK
dc.contributor.authorChan, LCen_HK
dc.contributor.authorLee, CKen_HK
dc.contributor.authorKwong, YLen_HK
dc.contributor.authorChim, CSen_HK
dc.contributor.authorChan, TKen_HK
dc.contributor.authorChiu, Een_HK
dc.contributor.authorLiang, Ren_HK
dc.date.accessioned2010-09-06T07:44:12Z-
dc.date.available2010-09-06T07:44:12Z-
dc.date.issued1998en_HK
dc.identifier.citationHematological Oncology, 1998, v. 16 n. 4, p. 163-168en_HK
dc.identifier.issn0278-0232en_HK
dc.identifier.urihttp://hdl.handle.net/10722/78557-
dc.description.abstractBetween 1990 and 1997, we performed 29 allogeneic BMTs for acute lymphoblastic leukemia (ALL) patients with HLA-identical sibs. Their median age was 31 years (range 15 to 43); there were 15 males and 14 females. The conditioning protocol was Cy-TBI (n= 15), VP16-Cy-TBI(n= 12), CBV (n= 1) and Bu-Cy (n = 1). Cyclosporin and methotrexate were used for GVHD prophylaxis. The median disease-free survival (DFS) was 12 months (range 1 to 92) with an actuarial 4-years DFS of 42.3 per cent. Three patientS died of transplant- related complications before 100 days. Relapse occurred in i 1 cases at a median time of 5 months (range 3 to 14). All nine patients relapsing within one year died form resistant leukemia. Three patients died of late treatment- related complications. There were 13 survivors (median follow-up 38 months, range 12-98), with 12 in remission. Only four had limited cGVHD, and all had 100 per cent performance scores. One patient also cleared her chronic hepatitis B carrier status due to acquired immunity. The DFS rates amongst CR1 cases and R1/CR2 cases were comparable (p=0.39). No long-term DFS is obtained from patients with resistant disease (n=4). The survival results for BMT at CR1 were superior to those using intensive chemotherapy consolidation (p=0.29), mainly due to poor late results in the chemotherapy arm. For young ALL patients with HLA-matched siblings, the option of BMT should be considered in light of local consolidation survival results.en_HK
dc.languageengen_HK
dc.publisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/3182en_HK
dc.relation.ispartofHematological Oncologyen_HK
dc.rightsHematological Oncology. Copyright © John Wiley & Sons Ltd.en_HK
dc.subjectAdult acute lymphoblastic leukemiaen_HK
dc.subjectBone marrow transplantationen_HK
dc.subject.meshAdolescenten_HK
dc.subject.meshAdulten_HK
dc.subject.meshBone Marrow Transplantationen_HK
dc.subject.meshCohort Studiesen_HK
dc.subject.meshCyclophosphamide - therapeutic useen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHumansen_HK
dc.subject.meshImmunosuppressive Agents - therapeutic useen_HK
dc.subject.meshMaleen_HK
dc.subject.meshPrecursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy - therapyen_HK
dc.subject.meshSurvival Analysisen_HK
dc.subject.meshTransplantation Conditioningen_HK
dc.subject.meshWhole-Body Irradiationen_HK
dc.titleAllogeneic bone marrow transplantation for adult acute lymphoblastic leukemia: A single-centre experienceen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0278-0232&volume=16&spage=163&epage=168&date=1998&atitle=Allogeneic+bone+marrow+transplantation+for+adult+acute+lymphoblastic+leukemia:+a+single-centre+experienceen_HK
dc.identifier.emailChan, LC:chanlc@hkucc.hku.hken_HK
dc.identifier.emailKwong, YL:ylkwong@hku.hken_HK
dc.identifier.emailChim, CS:jcschim@hku.hken_HK
dc.identifier.emailLiang, R:rliang@hku.hken_HK
dc.identifier.authorityChan, LC=rp00373en_HK
dc.identifier.authorityKwong, YL=rp00358en_HK
dc.identifier.authorityChim, CS=rp00408en_HK
dc.identifier.authorityLiang, R=rp00345en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/(SICI)1099-1069(199812)16:4<163::AID-HON634>3.0.CO;2-2en_HK
dc.identifier.pmid10414236en_HK
dc.identifier.scopuseid_2-s2.0-0032459594en_HK
dc.identifier.hkuros41657en_HK
dc.identifier.hkuros50228-
dc.identifier.hkuros49648-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0032459594&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume16en_HK
dc.identifier.issue4en_HK
dc.identifier.spage163en_HK
dc.identifier.epage168en_HK
dc.identifier.isiWOS:000081283600004-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridAu, WY=7202383089en_HK
dc.identifier.scopusauthoridLie, AKW=24284842400en_HK
dc.identifier.scopusauthoridMa, SK=37020910400en_HK
dc.identifier.scopusauthoridChan, LC=7403540707en_HK
dc.identifier.scopusauthoridLee, CK=7410162028en_HK
dc.identifier.scopusauthoridKwong, YL=7102818954en_HK
dc.identifier.scopusauthoridChim, CS=7004597253en_HK
dc.identifier.scopusauthoridChan, TK=7402687762en_HK
dc.identifier.scopusauthoridChiu, E=24827833600en_HK
dc.identifier.scopusauthoridLiang, R=26643224900en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats